Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 226
Report Code : HC-1286
Point of Care Diagnostics Market is poised to value USD 79932 million by 2028 end at a CAGR of 10.8% during the forecast period 2022 to 2028. The POC diagnostic devices can be used in doctors' offices, hospitals, and patient's homes to provide quick feedback on a wide range of medical tests. In this context, it refers to medical diagnostic tests that are performed during or near treatment, as in, when the patient is receiving treatment. Testing was historically limited to the medical laboratory, where specimens were sent away from the point of care and findings were awaited hours or days later, during which time care was continuing without the information needed. Point of Care Diagnostics Tests covers a variety of procedures, such as blood sugar testing, blood gas analysis, electrolyte balance testing, rapid blood clotting testing, rapid cardiac marker testing, urine strip testing, pregnancy testing, screening for drugs of abuse, screening for food pathogens, screening for hemoglobin, testing for infectious diseases, testing for cholesterol, and blood pathogens. In recent years, point-of-care diagnostics have become increasingly popular. There are a number of factors that are expected to drive the market for this technology, including convenience, reduced patient wait times, fewer or no follow-ups, accurate test results, rapid patient management, and improved healthcare delivery. There are more and more patients receiving treatment in the home for acute and chronic diseases, and thus the market for Point of Care Diagnostics devices is expected to grow as a result. The market will also be boosted by increasing investments in the field of Point of Care Diagnostics. Point of care tests detects HIV rapidly, allowing rapid treatment initiation, monitoring antiretroviral therapy and drug toxicity, and detecting opportunistic infections and related diseases. FutureWise Market Research has instantiated a report that provides an intricate analysis of Point of Care Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Point of Care Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Impact of COVID-19 on Point of Care Diagnostics Market: The University of Connecticut Health Center has developed a method based on CRISPR technology that can be used to detect diseases like COVID-19. This technology offers a highly specific, reliable and sensitive testing approach for diagnosing nuclei acid-based molecules. Furthermore, this method can be performed at room temperature, unlike the PCR-based methods, where a thermal cycler is required for maintaining temperature. But the current CRISPR detection technology requires multiple manual operations, separate amplification of nuclei acids in various reaction systems. These requirements complicate the tests, thereby risking of carrying contaminations owing to the transfer of amplified products. Key players included in the global point-of-care diagnostics industry are: Abbott, AccuBioTech, BioMérieux SA, Bio-Rad Laboratories, Becton, Dickinson, and Company, Chembio Diagnostics, Danaher, EKF Diagnostics, F. Hoffmann-La Roche, Instrumentation Laboratory, Johnson & Johnson, Nova, PTS Diagnostics, Sekisui Diagnostic, Siemens Healthineers, Sinocare Inc., Sysmex Corporation, Trinity Biotech, Trividia Health Inc., QIAGEN, Quidel. Point of Care Diagnostics Market Segmentation: By Product • Glucose Monitoring Products o Strips o Meters o Lancets & Lancing Platform • Cardiometabolic Testing Products o Cardia Marker Testing Products o Blood Gas/Electrolytes Testing Products o HBA1C Testing Products • Infectious Disease Testing Products o HIV testing Products o Hepatitis C Testing Products o Sexually Transmitted Disease (STD) Testing Products o Healthcare-Associated Infection (HAI) Testing Products o Respiratory Infection Testing Products o Tropical Disease Testing Products o Other Infectious Disease testing Products • Coagulation Testing Products o PT/INR Testing Products o Activated Clotting Time (ACT/APTT) Testing Products • Pregnancy and Fertility Testing Products o Tumour/Cancer Marker Testing Products o Urinalysis Testing Products o Cholesterol Testing Products o Hematology testing Products o Drug-of-Abuse Testing Products o Fecal Occult Testing Products o Other POC Products By Platform Agglutination Assays Immunoassays Biosensors Dipsticks Lateral Flow Assays Microfluidics Molecular Diagnostics Solid Phase By Mode Prescription-Based Testing OTC Testing By End User Home Care/ Self Testing Physician Offices and Outpatient Centers Hospitals Research Laboratories Other End Users By Region North America Europe Asia Pacific Latin America Middle East & Africa Point of Care Diagnostics Market Sample Video: Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global market by product, by platform, by mode, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The POC diagnostic devices can be used in doctors' offices, hospitals, and patient's homes to provide quick feedback on a wide range of medical tests. In this context, it refers to medical diagnostic tests that are performed during or near treatment, as in, when the patient is receiving treatment. Testing was historically limited to the medical laboratory, where specimens were sent away from the point of care and findings were awaited hours or days later, during which time care was continuing without the information needed. Point of Care Diagnostics Tests covers a variety of procedures, such as blood sugar testing, blood gas analysis, electrolyte balance testing, rapid blood clotting testing, rapid cardiac marker testing, urine strip testing, pregnancy testing, screening for drugs of abuse, screening for food pathogens, screening for hemoglobin, testing for infectious diseases, testing for cholesterol, and blood pathogens. In recent years, point-of-care diagnostics have become increasingly popular. There are a number of factors that are expected to drive the market for this technology, including convenience, reduced patient wait times, fewer or no follow-ups, accurate test results, rapid patient management, and improved healthcare delivery. There are more and more patients receiving treatment in the home for acute and chronic diseases, and thus the market for Point of Care Diagnostics devices is expected to grow as a result. The market will also be boosted by increasing investments in the field of Point of Care Diagnostics. Point of care tests detects HIV rapidly, allowing rapid treatment initiation, monitoring antiretroviral therapy and drug toxicity, and detecting opportunistic infections and related diseases.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Point of Care Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Point of Care Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Impact of COVID-19 on Point of Care Diagnostics Market:
The University of Connecticut Health Center has developed a method based on CRISPR technology that can be used to detect diseases like COVID-19. This technology offers a highly specific, reliable and sensitive testing approach for diagnosing nuclei acid-based molecules. Furthermore, this method can be performed at room temperature, unlike the PCR-based methods, where a thermal cycler is required for maintaining temperature. But the current CRISPR detection technology requires multiple manual operations, separate amplification of nuclei acids in various reaction systems. These requirements complicate the tests, thereby risking of carrying contaminations owing to the transfer of amplified products.
Key players included in the global point-of-care diagnostics industry are:
Abbott, AccuBioTech, BioMérieux SA, Bio-Rad Laboratories, Becton, Dickinson, and Company, Chembio Diagnostics, Danaher, EKF Diagnostics, F. Hoffmann-La Roche, Instrumentation Laboratory, Johnson & Johnson, Nova, PTS Diagnostics, Sekisui Diagnostic, Siemens Healthineers, Sinocare Inc., Sysmex Corporation, Trinity Biotech, Trividia Health Inc., QIAGEN, Quidel.
Point of Care Diagnostics Market Segmentation:
By Product
• Glucose Monitoring Products o Strips o Meters o Lancets & Lancing Platform • Cardiometabolic Testing Products o Cardia Marker Testing Products o Blood Gas/Electrolytes Testing Products o HBA1C Testing Products • Infectious Disease Testing Products o HIV testing Products o Hepatitis C Testing Products o Sexually Transmitted Disease (STD) Testing Products o Healthcare-Associated Infection (HAI) Testing Products o Respiratory Infection Testing Products o Tropical Disease Testing Products o Other Infectious Disease testing Products • Coagulation Testing Products o PT/INR Testing Products o Activated Clotting Time (ACT/APTT) Testing Products • Pregnancy and Fertility Testing Products o Tumour/Cancer Marker Testing Products o Urinalysis Testing Products o Cholesterol Testing Products o Hematology testing Products o Drug-of-Abuse Testing Products o Fecal Occult Testing Products o Other POC Products
By Platform
By Mode
By End User
By Region
Point of Care Diagnostics Market Sample Video:
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data From Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data From Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3.Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Point of Care Diagnostics MarketVariables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Point of Care Diagnostics Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Point of Care Diagnostics MarketAnalysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Point of Care Diagnostics Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Glucose Monitoring Products 7.1.1. Strips 7.1.2. Meters 7.1.3. Lancets and Lancing Platform 7.2. Cardiometabolic Testing Products 7.2.1. Cardia Marker Testing Products 7.2.2. Blood Gas/ Electrolytes Testing Products 7.2.3. HBA1C Testing Products 7.3. Infectious Disease Testing Products 7.3.1. Influenza Testing Products 7.3.2. HIV Testing Products 7.3.3. Hepatitis C Testing Products 7.3.4. Sexually Transmitted Disease Testing Products 7.3.5. Healthcare Associated Infection Testing Products 7.3.6. Respiratory Infection Testing Products 7.3.7. Tropical Disease Testing Products 7.3.8. Other Infectious Disease Testing Products 7.4. Coagulation Testing Products 7.4.1. PT/INR Testing Products 7.4.2. Activated Clotting Time Testing Products 7.5. Pregnancy and Fertility Testing Products 7.6. Tumor/ Cancer Marker Testing Products 7.7. Urinalysis Testing Products 7.8. Cholesterol Testing Products 7.9. Hematology Testing Products 7.10. Drug-of-Abuse Testing Products 7.11. Fecal Occult Testing Products 7.12. Other POC Testing Products 8. Point of Care Diagnostics Market, By Platform Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Agglutination Assays 8.2. Immunoassays 8.3. Biosensors 8.4. Dipsticks 8.5. Lateral Flow Assays 8.6. Microfluidics 8.7. Molecular Diagnostics 8.8. Solid Phase 9. Point of Care Diagnostics Market, By Mode Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Prescription-Based Testing 9.2. OTC Testing 10. Point of Care Diagnostics Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Home Care/ Self Testing 10.2. Physician Offices and Outpatient Centers 10.3. Hospitals 10.4. Research Laboratories 10.5. Other End Users 11. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Regional Market Trends 12.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.3.1. Brazil 12.3.2. Venezuela 12.3.3. Argentina 12.3.4. Rest of Latin America 12.4. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Switzerland 13.2.9.Rest of Western Europe 13.4. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. Singapore 14.2.4. India 14.2.5. Australia and New Zealand 14.2.6. ASEAN 14.2.7. South Korea 14.2.8. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 17.1 ABBOTT 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2 ACCUBIOTECH 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3 BIOMERIEUX SA 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4 BIO RAD LABORATORIES 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5 BECTON DICKINSON AND CO. 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6 CHEMBIO DIAGNOSTICS 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7 DANAHER 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8 EKF DIAGNOSTICS 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9 F-HOFFMANN LA ROCHE 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10 INSTRUMENTATION LABORATORY 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11 JOHNSON & JOHNSON 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12 NOVA 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13 PTS DIAGNOSTICS 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14 SEKISUI DIAGNOSTICS 17.14.1. Company Overview 17.14.2. Product Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15 SEIMENS HEALTHINEERS 17.15.1. Company Overview 17.15.2. Product Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 18. Impact of COVID-19 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics